title: Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups.
abstract: The European Organization for Research and Treatment of Cancer (EORTC) 22861 randomised trial established that combined radiochemotherapy is the standard treatment for locally advanced anal cancer. This EORTC phase II study (#22953) tests the feasibility of reducing the gap between sequences to 2 weeks, to deliver Mitomycin C (MMC) in each radiotherapy sequence and 5-FU continuously during the treatment. The first sequence consisted of 36 Gy over 4 weeks. 5-FU 200 mg/m(2)/days 1-26, MMC 10 mg/m(2)/day 1 gap 16 days. Then a second sequence of 23.4 Gy over 17 days, 5-FU 200 mg/m(2)/days 1-17 and, MMC 10 mg/m(2)/day 1 was given. 43 patients with a World Health Organization (WHO) status of 0 (n=27) or 1 (n=16) and with T2-T4, N0-3 tumours were included. Compliance with the planned treatment, doses and duration was 93%. The complete response rate was 90.7%. Grade 3 toxicities of 28, 12 and 2% were observed for skin, diarrhoea and haematological toxicities, respectively. The 3-year estimated rates for trials 22861 and 22953 are: 68 and 88% for local control; 72 and 81% for colostomy-free interval, 62 and 84% for severe late toxicity-free interval, and 70 and 81% for survival, respectively. The 22953 scheme is feasible and the results are promising. This is now considered as the new standard scheme by the EORTC.
authors.affiliation: Radiotherapy Department, Besançon University Hospital, Besançon, France. jean-francois.bosset@ufc-chu.univ-fcomte.fr
authors.forename: J F
authors.initials: JF
authors.lastname: Bosset
authors.forename: F
authors.initials: F
authors.lastname: Roelofsen
authors.forename: D A L
authors.initials: DA
authors.lastname: Morgan
authors.forename: V
authors.initials: V
authors.lastname: Budach
authors.forename: P
authors.initials: P
authors.lastname: Coucke
authors.forename: J J
authors.initials: JJ
authors.lastname: Jager
authors.forename: E
authors.initials: E
authors.lastname: Van der Steen-Banasik
authors.forename: N
authors.initials: N
authors.lastname: Trivière
authors.forename: G
authors.initials: G
authors.lastname: Stüben
authors.forename: M
authors.initials: M
authors.lastname: Puyraveau
authors.forename: M
authors.initials: M
authors.lastname: Mercier
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001005:Anus Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D011879:Radiotherapy Dosage
chemical_list: D016685:Mitomycin; D005472:Fluorouracil